Apheresis Market - Global Forecasts | Market Segmentation | Major Leaders | Emerging Trends

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies. 

The global apheresis market is projected to reach USD 2.7 billion by 2025 from USD 1.7 billion in 2019, at a CAGR of 8.1% during the forecast period.

The rising prevalence of chronic diseases and the growing number of trauma & injury cases, the rising demand for blood components and growing concerns regarding blood safety, and the favorable reimbursement for apheresis procedures are the major factors driving the growth of this market. 

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950

Recent Developments:

# In July 2019, Baxter International Inc. (US) launched the PrisMax system in the US.
# In June 2019, Toray Medical Co. Ltd. (Japan) launched the TORAMYXIN device in the European region.
# In October 2019, Terumo BCT (US) collaborated with the UniCAR-Therapy Bio-Medicine Technology Co. (China). This collaboration aimed at advancing CAR T-cell therapies by creating a new Shanghai Center of Excellence. This development also helped Terumo widen its applications of apheresis and leukapheresis procedures.
# In August 2017, Fresenius Medical Care (Germany) acquired NxStage Medical, Inc. (US). This acquisition enabled Fresenius Medical Care to further expand its presence in the renal care and critical care area.

On the basis of end user, the apheresis market has been segmented into blood collection centers and blood component providers, hospitals and transfusion centers, and other end users. The hospitals and transfusion centers segment is estimated to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing adoption of therapeutic apheresis in the treatment of various diseases, growing indications of therapeutic apheresis, and rising awareness of apheresis as a therapy.

North America accounted for the largest market share in 2018

North America accounted for the largest share of the apheresis market in 2018, followed by Europe. The large share of this region can be attributed to easier accessibility to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.

Critical questions the report answers:

# Where will these developments take the industry in the mid-to-long term?|
# Who are the major end users in the apheresis market, and what are the benefits they avail by implementing apheresis technology?
# What are the recent trends in the apheresis market?
# What are the major market dynamics and their impact on overall market growth?
# What is the global scenario of the apheresis market?

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=950

The key players of this market focus on increasing their market presence with the adoption of both organic and inorganic growth strategies. These include product launches, agreements, partnerships, collaborations, and acquisitions.

The key players in the global apheresis market are Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), and Nikkiso Co., Ltd. (Japan). 

Terumo BCT, Inc. (US) is one of the leading players in the apheresis market and accounted for the largest share in 2018. The company is known for its diversified product offerings in the field of apheresis. Terumo’s products include the Spectra Optia, COBE Spectra, and Trima Accel, and these are widely adopted by blood centers, blood component providers, hospitals, and transfusion centers for donor & therapeutic apheresis purposes. The company has a significant global footprint owing to its strong sales and distribution network. 

Fresenius SE & Co. KGaA (Germany) Fresenius is a global player in the apheresis market, with wide geographic coverage. The company has maintained its leading position in the market through its strong distribution networks across the Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. The company offers apheresis systems and related disposables for both donor & therapeutic apheresis through its Fresenius Kabi and Fresenius Medical Care business segments. 

Haemonetics Corporation (US) Haemonetics Corporation is a key competitor in the apheresis market for both the collection of cells and therapeutic apheresis. The company has a strong product profile in automated blood component collection. Haemonetics also has a wide geographic presence across the US, Europe, Japan, and Asia, which enables it to cater to its customers across the globe. Around 62% of the company’s revenue is generated from the US market.

Read More Detailed Article@   
https://www.marketsandmarkets.com/Market-Reports/apheresis-market-950.html